Brief: US Awards Moderna $1.5 Billion For Coronavirus Vaccines

Moderna Therapeutics CEO Stéphane Bancel.

Photo credit: World Economic Forum / Boris Baldinger, under Creative Commons license

Biotech company Moderna has announced that it's received an order from the U.S. government for 100 million doses of a planned coronavirus vaccine for an aggregate cost of $1.5 billion. Under the terms of the deal, the U.S. is also reserving the option to order an additional 400 million doses from Moderna.

As part of Operation Warp Speed, a public–private partnership initiated by the US government to facilitate and accelerate the the development, manufacturing, and distribution of potential COVID-19 vaccines and treatments, the U.S. has now committed a total of $2.5 billion for early access to potential vaccines.

Moderna's planned coronavirus vaccine is currently undergoing Phase 3 clinical trials.